These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


507 related items for PubMed ID: 26963837

  • 1. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.
    Tustian AD, Endicott C, Adams B, Mattila J, Bak H.
    MAbs; 2016; 8(4):828-38. PubMed ID: 26963837
    [Abstract] [Full Text] [Related]

  • 2. Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity.
    Tustian AD, Laurin L, Ihre H, Tran T, Stairs R, Bak H.
    Biotechnol Prog; 2018 May; 34(3):650-658. PubMed ID: 29464924
    [Abstract] [Full Text] [Related]

  • 3. Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics.
    Ching KH, Berg K, Reynolds K, Pedersen D, Macias A, Abdiche YN, Harriman WD, Leighton PA.
    MAbs; 2021 May; 13(1):1862451. PubMed ID: 33491549
    [Abstract] [Full Text] [Related]

  • 4. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D, Vaks L, Dror S, Nahary L, Benhar I.
    Methods Mol Biol; 2019 May; 1904():431-454. PubMed ID: 30539485
    [Abstract] [Full Text] [Related]

  • 5. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
    Moore GL, Bernett MJ, Rashid R, Pong EW, Nguyen DT, Jacinto J, Eivazi A, Nisthal A, Diaz JE, Chu SY, Muchhal US, Desjarlais JR.
    Methods; 2019 Feb 01; 154():38-50. PubMed ID: 30366098
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
    Cooke HA, Arndt J, Quan C, Shapiro RI, Wen D, Foley S, Vecchi MM, Preyer M.
    MAbs; 2018 Feb 01; 10(8):1248-1259. PubMed ID: 30215570
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J, Ghayur T.
    Methods Enzymol; 2012 Feb 01; 502():25-41. PubMed ID: 22208980
    [Abstract] [Full Text] [Related]

  • 12. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ, Zurini M.
    Biotechnol J; 2012 Dec 01; 7(12):1444-50. PubMed ID: 23125076
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies.
    Wranik BJ, Christensen EL, Schaefer G, Jackman JK, Vendel AC, Eaton D.
    J Biol Chem; 2012 Dec 21; 287(52):43331-9. PubMed ID: 23118228
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 26.